What is HC Wainwright’s Forecast for Genelux Q2 Earnings?

Genelux Co. (NASDAQ:GNLX) – Equities researchers at HC Wainwright lifted their Q2 2025 EPS estimates for Genelux in a report released on Wednesday, May 7th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings of ($0.22) per share for the quarter, up from their prior estimate of ($0.24). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for Genelux’s current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Genelux’s Q3 2025 earnings at ($0.25) EPS, FY2025 earnings at ($0.96) EPS, FY2026 earnings at ($0.97) EPS, FY2027 earnings at ($0.68) EPS, FY2028 earnings at $0.44 EPS and FY2029 earnings at $1.44 EPS.

Separately, Benchmark decreased their target price on Genelux from $25.00 to $23.00 and set a “speculative buy” rating for the company in a research report on Thursday. Four research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $17.75.

Genelux Stock Performance

Shares of NASDAQ GNLX opened at $2.96 on Friday. Genelux has a 52-week low of $1.60 and a 52-week high of $5.89. The firm has a market capitalization of $111.70 million, a price-to-earnings ratio of -3.12 and a beta of -0.33. The stock has a 50 day moving average price of $2.96 and a 200 day moving average price of $3.11.

Genelux (NASDAQ:GNLX) last issued its earnings results on Thursday, May 8th. The company reported ($0.21) EPS for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.03.

Hedge Funds Weigh In On Genelux

Institutional investors have recently bought and sold shares of the business. Woodward Diversified Capital LLC increased its holdings in shares of Genelux by 15.2% in the 1st quarter. Woodward Diversified Capital LLC now owns 1,461,113 shares of the company’s stock valued at $3,945,000 after acquiring an additional 192,808 shares during the period. Geode Capital Management LLC boosted its position in Genelux by 39.7% during the third quarter. Geode Capital Management LLC now owns 316,160 shares of the company’s stock valued at $749,000 after purchasing an additional 89,854 shares in the last quarter. Marshall Wace LLP grew its stake in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company’s stock valued at $368,000 after purchasing an additional 52,958 shares during the last quarter. LPL Financial LLC raised its holdings in Genelux by 72.3% in the fourth quarter. LPL Financial LLC now owns 94,144 shares of the company’s stock worth $222,000 after purchasing an additional 39,516 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Genelux during the first quarter valued at about $68,000. 37.33% of the stock is owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.